U.S. markets closed

Ipsen S.A. (IPSEY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
24.89+0.45 (+1.84%)
At close: 3:27PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close24.44
Open25.10
Bid0.00 x 0
Ask0.00 x 0
Day's Range24.89 - 25.10
52 Week Range18.20 - 27.10
Volume499
Avg. Volume2,619
Market Cap8.347B
Beta (5Y Monthly)1.00
PE Ratio (TTM)12.56
EPS (TTM)1.98
Earnings DateN/A
Forward Dividend & Yield0.28 (1.16%)
Ex-Dividend DateJun 03, 2020
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Fusion Pharmaceuticals Announces Closing of Acquisition of IPN-1087, a Small Molecule Targeting NTSR1, from Ipsen
    CNW Group

    Fusion Pharmaceuticals Announces Closing of Acquisition of IPN-1087, a Small Molecule Targeting NTSR1, from Ipsen

    Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced it has completed the acquisition of Ipsen's (Euronext: IPN; ADR; IPSEY) intellectual property and assets related to IPN-1087. IPN-1087 is a small molecule targeting neurotensin receptor 1 (NTSR1), a protein expressed on multiple solid tumor types. Fusion intends to use IPN-1087 to create an alpha-emitting radiopharmaceutical, FPI-2059, targeting solid tumors expressing NTSR1.

  • Royalty Pharma Buys Royalty Interest In Cabozantinib Products From GSK
    Benzinga

    Royalty Pharma Buys Royalty Interest In Cabozantinib Products From GSK

    Royalty Pharma Plc (NASDAQ: RPRX) has acquired a royalty interest in Cabometyx and Cometriq from GlaxoSmithKline Plc (NYSE: GSK) for an upfront payment of $342 million. Under this transaction's terms, Royalty Pharma has purchased royalties on cabozantinib products' net sales in non-U.S. markets through the entire duration of the royalty and royalties on net sales in the U.S. through September 2026 after which U.S. royalties will remain with GSK. The deal also includes up to $50 million in additional payments contingent on the achievement of cabozantinib's regulatory approvals for prostate cancer and lung cancer in the U.S. and Europe. Cabometyx and Cometriq are marketed by Exelixis Inc (NASDAQ: EXEL) in the U.S. and their partner Ipsen (OCTMKTS: IPSEY) in regions outside the U.S. and Japan. Cabometyx is marketed in Japan by Exelixis' partner Takeda Pharmaceutical Co Ltd (NYSE: TAK) GSK is entitled to a 3% royalty on worldwide net sales of cabozantinib products due to its 2002 collaboration with Exelixis. In 2020, sales of Cabometyx and Cometriq reported by Exelixis and Ipsen were $742 million and €289 million, respectively. Price Action: RPRX shares are trading 0.2% lower at $43.53 in the market trading session on the last check Thursday. See more from BenzingaClick here for options trades from BenzingaEMA May Issue Updated Recommendation If AstraZeneca Jab-Clot Link Is Established: ReportPfizer-BioNTech's COVID-19 Vaccine Gives 100% Protection In Adolescents© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Fusion Pharmaceuticals to Expand Pipeline with Acquisition of IPN-1087, a Small Molecule Targeting NTSR1, from Ipsen
    PR Newswire

    Fusion Pharmaceuticals to Expand Pipeline with Acquisition of IPN-1087, a Small Molecule Targeting NTSR1, from Ipsen

    Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced it has entered into an asset purchase agreement (APA) to acquire Ipsen's (Euronext: IPN; ADR; IPSEY) intellectual property and assets related to IPN-1087. IPN-1087 is a small molecule targeting neurotensin receptor 1 (NTSR1), a protein expressed on multiple solid tumor types. Fusion intends to use IPN-1087 to create an alpha-emitting radiopharmaceutical, FPI-2059, targeting solid tumors expressing NTSR1.